Optimal aspirin dose in acute coronary syndromes: An emerging consensus

James J. Dinicolantonio; Nicholas B. Norgard; Pascal Meier; Carl J. Lavie; James H. O'Keefe; Asfandyar K. Niazi; Saurav Chatterjee; Kathleen A. Packard; Fabrizio D'Ascenzo; Enrico Cerrato; Giuseppe Biondi-Zoccai; Sripal Bangalore; Flavio D. Fuchs; Victor L. Serebruany

doi:10.2217/fca.14.7

Optimal aspirin dose in acute coronary syndromes: An emerging consensus

James J. Dinicolantonio, Nicholas B. Norgard, Pascal Meier, Carl J. Lavie, James H. O'Keefe, Asfandyar K. Niazi, Saurav Chatterjee, Kathleen A. Packard, Fabrizio D'Ascenzo, Enrico Cerrato, Giuseppe Biondi-Zoccai, Sripal Bangalore, Flavio D. Fuchs, Victor L. Serebruany

School of Medicine

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Numerous clinical trials testing the efficacy of aspirin for the secondary prevention of cardiovascular disease have been published. We reviewed the literature pertaining to aspirin dose in acute coronary syndrome patients. Clinical trials assessing the comparative efficacy of different doses of aspirin are scarce. This complex antiplatelet therapy landscape makes it difficult to identify the best aspirin dose for optimizing efficacy and minimizing risk of adverse events, while complying with the various guidelines and recommendations. Despite this fact, current evidence suggests that aspirin doses of 75-100 mg/day may offer the optimal benefit:risk ratio in acute coronary syndrome patients.

Original language	English (US)
Pages (from-to)	291-300
Number of pages	10
Journal	Future Cardiology
Volume	10
Issue number	2
DOIs	https://doi.org/10.2217/fca.14.7
State	Published - 2014

Keywords

Acute coronary syndrome
aspirin
bleeding
clopidogrel

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Molecular Medicine
General Medicine

Access to Document

10.2217/fca.14.7

Cite this

Dinicolantonio, J. J., Norgard, N. B., Meier, P., Lavie, C. J., O'Keefe, J. H., Niazi, A. K., Chatterjee, S., Packard, K. A., D'Ascenzo, F., Cerrato, E., Biondi-Zoccai, G., Bangalore, S., Fuchs, F. D., & Serebruany, V. L. (2014). Optimal aspirin dose in acute coronary syndromes: An emerging consensus. Future Cardiology, 10(2), 291-300. https://doi.org/10.2217/fca.14.7

@article{96fa127ecfab4928ae4f47d12db6c64a,

title = "Optimal aspirin dose in acute coronary syndromes: An emerging consensus",

abstract = "Numerous clinical trials testing the efficacy of aspirin for the secondary prevention of cardiovascular disease have been published. We reviewed the literature pertaining to aspirin dose in acute coronary syndrome patients. Clinical trials assessing the comparative efficacy of different doses of aspirin are scarce. This complex antiplatelet therapy landscape makes it difficult to identify the best aspirin dose for optimizing efficacy and minimizing risk of adverse events, while complying with the various guidelines and recommendations. Despite this fact, current evidence suggests that aspirin doses of 75-100 mg/day may offer the optimal benefit:risk ratio in acute coronary syndrome patients.",

keywords = "Acute coronary syndrome, aspirin, bleeding, clopidogrel",

author = "Dinicolantonio, {James J.} and Norgard, {Nicholas B.} and Pascal Meier and Lavie, {Carl J.} and O'Keefe, {James H.} and Niazi, {Asfandyar K.} and Saurav Chatterjee and Packard, {Kathleen A.} and Fabrizio D'Ascenzo and Enrico Cerrato and Giuseppe Biondi-Zoccai and Sripal Bangalore and Fuchs, {Flavio D.} and Serebruany, {Victor L.}",

year = "2014",

doi = "10.2217/fca.14.7",

language = "English (US)",

volume = "10",

pages = "291--300",

journal = "Future Cardiology",

issn = "1479-6678",

publisher = "Future Medicine Ltd.",

number = "2",

}

TY - JOUR

T1 - Optimal aspirin dose in acute coronary syndromes

T2 - An emerging consensus

AU - Dinicolantonio, James J.

AU - Norgard, Nicholas B.

AU - Meier, Pascal

AU - Lavie, Carl J.

AU - O'Keefe, James H.

AU - Niazi, Asfandyar K.

AU - Chatterjee, Saurav

AU - Packard, Kathleen A.

AU - D'Ascenzo, Fabrizio

AU - Cerrato, Enrico

AU - Biondi-Zoccai, Giuseppe

AU - Bangalore, Sripal

AU - Fuchs, Flavio D.

AU - Serebruany, Victor L.

PY - 2014

Y1 - 2014

N2 - Numerous clinical trials testing the efficacy of aspirin for the secondary prevention of cardiovascular disease have been published. We reviewed the literature pertaining to aspirin dose in acute coronary syndrome patients. Clinical trials assessing the comparative efficacy of different doses of aspirin are scarce. This complex antiplatelet therapy landscape makes it difficult to identify the best aspirin dose for optimizing efficacy and minimizing risk of adverse events, while complying with the various guidelines and recommendations. Despite this fact, current evidence suggests that aspirin doses of 75-100 mg/day may offer the optimal benefit:risk ratio in acute coronary syndrome patients.

AB - Numerous clinical trials testing the efficacy of aspirin for the secondary prevention of cardiovascular disease have been published. We reviewed the literature pertaining to aspirin dose in acute coronary syndrome patients. Clinical trials assessing the comparative efficacy of different doses of aspirin are scarce. This complex antiplatelet therapy landscape makes it difficult to identify the best aspirin dose for optimizing efficacy and minimizing risk of adverse events, while complying with the various guidelines and recommendations. Despite this fact, current evidence suggests that aspirin doses of 75-100 mg/day may offer the optimal benefit:risk ratio in acute coronary syndrome patients.

KW - Acute coronary syndrome

KW - aspirin

KW - bleeding

KW - clopidogrel

UR - http://www.scopus.com/inward/record.url?scp=84899576762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899576762&partnerID=8YFLogxK

U2 - 10.2217/fca.14.7

DO - 10.2217/fca.14.7

M3 - Article

C2 - 24762255

AN - SCOPUS:84899576762

SN - 1479-6678

VL - 10

SP - 291

EP - 300

JO - Future Cardiology

JF - Future Cardiology

IS - 2

ER -

Optimal aspirin dose in acute coronary syndromes: An emerging consensus

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this